News-Medical.Net on MSN1d
New trial shows oral semaglutide reduces cardiovascular events in diabetes patientsBoth the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
News-Medical.Net on MSN17h
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
Stocktwits on MSN6d
Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment SoarsVivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...
Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
The cardiovascular safety of oral semaglutide, a glucagon-like peptide ... We thank Sonia Vyskocilova, Ph.D., for providing medical writing support on earlier drafts of the manuscript, including ...
March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ ... promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback